Texas Couple Each Sentenced to Seven Years in Prison for Forced Labor and Related Offenses

Houston, Texas - U.S. District Court Judge Reid O’Connor sentenced defendants Mohamed Toure, 58, and Denise Cros-Toure, 58, of Southlake, Texas, to seven years in prison each and ordered them to pay $288,620.24 in restitution. A federal jury convicted the defendants of forced labor, conspiracy to commit alien harboring, and alien harboring on January 11 following a four-day trial.

Medicare Trustees Report

Washington, DC - The Medicare Trustees report highlights that the Medicare Hospital Insurance trust fund is expected to be insolvent by 2026, as the program’s finances remain in peril.  This report highlights the need for serious-minded legislators to partner with the Administration on commonsense, bipartisan reforms that will lower costs and eliminate fraud and abuse, preserving the program for future generations.  

NIH funds study in four states to reduce opioid related deaths by 40 percent over three years

Washington, DC - As part of Health and Human Services Secretary Alex Azar’s cross-cutting Department initiatives to address the opioid epidemic, the National Institutes of Health today selected four research sites for the HEALing Communities Study in four states hard hit by the opioid crisis.

President Donald J. Trump is Taking Action to Reduce Visa Overstays and Uphold the Rule of Law

Washington, DC - "We have laws that need to be followed to keep Americans safe and to protect the integrity of a system where, right now, there are millions of people who are waiting in line to come to America to seek the American Dream." ~ President Donald J. Trump

Novel antibody may suppress HIV for up to four months

Washington, DC - Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV.